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Abstract: Delivery of inhaled medications via an inhaler device underpins the effectiveness 
of treatment for patients with chronic obstructive pulmonary disease (COPD). Correct inhaler 
technique among patients is also a predictor of achieving treatment compliance and adherence. 
Reporting of patient satisfaction with inhalers is therefore gaining increasing attention and is now 
recognized as an important patient-reported outcome in clinical trials involving patients with COPD 
or asthma. In this cross-sectional study, we use the validated Patient Satisfaction and Preference 
Questionnaire (PASAPQ) to assess the handling and satisfaction for Respimat® Soft Mist™ Inhaler 
(SMI) compared with the Breezhaler® dry powder inhaler (DPI) among patients with COPD in 
Spain. Patients were already assigned to therapy with either SPIRIVA® (tiotropium) Respimat® or 
with Hirobriz®/Onbrez®/Oslif® (indacaterol) Breezhaler® for at least 3 but not more than 6 months 
before completing the PASAPQ at a single visit to the study site. The primary endpoint of the trial 
was the mean total PASAPQ score. Secondary endpoints were the performance score domain of 
the PASAPQ, the convenience score domain of the PASAPQ, and the overall satisfaction score 
of the PASAPQ. For the primary endpoint, the mean PASAPQ total score in the Respimat® and 
Breezhaler® groups was 80.7 and 79.9, respectively (difference of 0.8, 95% confidence interval 
[CI] -2.9 to 4.5; P=0.67). The mean total performance scores were 82.5 and 78.2 (difference of 4.3, 
95% CI -0.3 to 8.9; P=0.06), and the mean total convenience scores were 78.6 and 81.9 (difference 
of -3.3, 95% CI -7.0 to 0.4; P=0.08) for the Respimat® and Breezhaler® groups, respectively. 
Patients gave the Respimat® SMI and the Breezhaler® DPI overall satisfaction PASAPQ scores of 
6.0 and 5.9, respectively, which shows that patients were satisfied with these inhalers.
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Introduction
The cornerstone of treatment delivery for chronic obstructive pulmonary disease 
(COPD) involves administration of medications through inhaler devices.1 Inhaler 
choice and handling of inhalation devices are key factors for the effectiveness of 
treatment.2–4 Therefore, patients should receive appropriate guidance on the correct 
use of the inhaler with regular follow-up to ensure treatment compliance.3,5,6
Patient satisfaction with their inhaler is an acknowledged predictor of treatment 
adherence.7–10 In a large, multinational, cross-sectional, real-world survey reported by 
Chrystyn et al,10 patient satisfaction with their inhaler was closely linked to treatment 
compliance and loosely associated with fewer exacerbations and lower utilization of 
health-care resources.10 Reporting of patient satisfaction with inhalers is therefore 
gaining increasing attention and is now recognized as an important patient-reported 
outcome in clinical trials involving patients with COPD or asthma.1
Measurement of inhaler satisfaction requires the use of reliable and validated instru-
ments such as the Patient Satisfaction and Preference Questionnaire (PASAPQ).11 Details 
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on the development and use of the PASAPQ have been pub-
lished elsewhere.11 The PASAPQ was designed to be easily 
understood and self-administered by patients with COPD or 
asthma. It also has an added advantage in that it is device- and 
treatment-independent, making it widely applicable to respira-
tory treatments. The PASAPQ has therefore been adopted as 
one of the principal tools for reporting patient satisfaction/
preference with a variety of inhalation devices, including 
metered-dose inhalers (MDIs), dry powder inhalers (DPIs), 
and, more recently, the Respimat® Soft Mist™ Inhaler (SMI, 
Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, 
Germany).12 In this study, we report on the findings from a 
cross-sectional study designed to assess the patient handling 
and satisfaction for Respimat® SMI (Boehringer Ingelheim 
Pharma GmbH & Co KG) compared with the Breezhaler® 
DPI13 (Novartis Pharma S.A.S., Paris, France) under everyday 
conditions of practical use in patients with COPD in Spain.
Methods
study design
This was a multicenter open-label, cross-sectional, post-
marketing surveillance study.
study population
Patients with COPD were eligible for the study if they were 
already assigned to therapy with either SPIRIVA® (tiotropium) 
Respimat® (Boehringer Ingelheim Pharma GmbH & Co KG) 
or with Hirobriz®/Onbrez®/Oslif® (indacaterol) Breezhaler® 
(Novartis Pharma S.A.S.) for at least 3 but not more than 6 
months before they were invited to complete the PASAPQ 
at a single visit to the study site. During this visit, data on the 
patients’ baseline characteristics, duration of COPD, relevant 
concomitant diagnoses, and concomitant medication were 
collected. Whether patients received training in the use of 
either inhaler at prescription was also documented at this visit. 
Inclusion criteria were men and women aged $40 years with 
a clinical diagnosis of COPD and confirmed by spirometry 
(a postbronchodilator forced expiratory volume in 1 second/
forced vital capacity ratio #0.7). Patients followed usual 
clinical practice of the participant sites and were stabilized 
with their existing medication. Patients were excluded for 
the following reasons: 1) they were previously included in 
this study or currently participating in another interventional 
study; 2) had visual, cognitive, or motor impairment that, as 
judged by the investigator, did not allow the patient to inde-
pendently read and complete the PASAPQ questionnaire; 3) 
they were being treated simultaneously with both inhalers: 
Respimat® and Breezhaler®.
All patients signed a written informed consent consistent 
with the International Conference on Harmonization–Good 
Clinical Practice (ICH–GCP) guidelines. The study was 
approved by the Ethics Commiittee of the Vall d’Hebron Uni-
versity Hospital, Barcelona, Spain.
endpoints
The primary endpoint of the trial was the mean total PASAPQ 
score. Secondary endpoints were the performance score 
domain of the PASAPQ, the convenience score domain 
of the PASAPQ, and the overall satisfaction score of the 
PASAPQ.
assessments
Patient inhaler device satisfaction was analyzed using the 
relevant components of the PASAPQ; this comprised 14 
items across three domains.11 Thirteen satisfaction ques-
tions were used to calculate the total score. Questions 1, 2, 
3, 4, 5, 10, and 11 comprise the performance domain and 
questions 6, 7, 8, 9, 12, and 13 comprise the convenience 
domain. Question 14 examined overall patient satisfaction 
score (Table S1). A stand-alone item relating to device 
preference and willingness to continue was omitted in this 
study because the trial design precluded the assessment 
of patient preference. Patients could only use one inhaler 
not both; they could not compare the performance of both 
inhalers and therefore state a preference. All questions were 
answered on a 7-point scale ranging from 1 to 7 (1= very 
dissatisfied, 2= dissatisfied, 3= somewhat dissatisfied, 4= 
neither dissatisfied nor satisfied, 5= somewhat satisfied, 6= 
satisfied, 7= very satisfied). To calculate the domain scores, 
the sum of the items within each domain was transformed 
to a 0–100-point scale.
statistical analyses
Descriptive statistics for N (number of nonmissing observa-
tions), mean, standard deviation (SD), minimum (min), 1st 
quartile, median, 3rd quartile, and maximum (max) were 
calculated for continuously distributed data and for ordered 
categorical data (ordinal data). Inferential statistics were 
used for the calculation of 95% confidence intervals (CIs) 
for the difference of the means of the total score and the 
performance and convenience domain scores. These analyses 
were performed using the Student’s t-test. The statistical 
analysis was conducted using a two-sided test. The primary 
analysis was based on the full analysis set, which included 
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Device handling and patient satisfaction in COPD
The study sample size was based on the calculation 
that 70 patients in each group would be required to have a 
90% power to detect a minimum 10-point difference in the 
mean PASAPQ score between patients using Respimat® or 
Breezhaler®, assuming that the common standard deviation is 
18.0 using a two-sample t-test with a 0.05 two-sided signifi-
cance level. To account for potential patients with no evaluable 
data, a total number of 75 patients per group was planned.
Missing data were handled as follows: both domain scores 
(performance and convenience) used the standard half-scale 
option for scoring (eg, responses for at least half of the items 
in the scale). Each patient had to answer at least half of the 
items in the domain to calculate a score for that domain at 
that time point. If the patient answered at least half of the 
items in the domain, values for missing items were imputed 
using the mean of the remaining, nonmissing items in that 
domain. For a comparison of patient baseline demographics, 
P-values were based on the chi-square test or Fisher’s exact 
test for the categorical variables, and on a two-sample t-test 
for the continuous variables.
Results
Patient characteristics
The study was conducted in 15 sites in Spain and enrolled 
154 patients with stable COPD. All patients completed the 
PASAPQ. Patients in the Respimat® and Breezhaler® groups 
were generally comparable in their baseline characteristics, 
prebronchodilator and postbronchodilator spirometry assess-
ments, disease progression and duration of COPD, smoking 
status, and level of device training received (Table 1). Before 
being prescribed Respimat® or Breezhaler® by their treating 
physician, 73 patients received training on using Respimat® 
compared with 76 patients who received training on the use 
of Breezhaler® (Table 1).
Patient satisfaction with inhaler 
performance and convenience
For the primary endpoint, there was not a statistically sig-
nificant difference in the mean PASAPQ total score between 
the Respimat® and Breezhaler® groups (80.7 and 79.9, 
respectively, difference of 0.8, 95% CI -2.9 to 4.5; P=0.67) 
(Figure 1; Table 2). For the secondary endpoints of mean total 
performance and convenience domain scores, there were no 
differences in scores between the Respimat® and Breezhaler® 
groups (mean performance score: 82.5 and 78.2, respectively, 
difference of 4.3, 95% CI -0.3 to 8.9; P=0.06; and mean 
convenience score: 78.6 and 81.9, respectively, difference of 
-3.3, 95% CI -7.0 to 0.4; P=0.08) (Figure 1; Table 2). This 
was also true for the secondary endpoint of overall patient 
satisfaction score (difference of 0.1, 95% CI -0.3 to 0.4; 
P=0.70). For both the Respimat® and Breezhaler® groups, 
the distributions in patient total PASAPQ scores were com-
parable. This distribution was mirrored in the performance 
and convenience domain scores, which showed that .95% of 
patients were satisfied with the performance and convenience 
of using their assigned inhaler (scores .60 show that patients 
are satisfied) (Figure 2).
subgroup analyses
Stratification of the PASAPQ scores for performance, con-
venience, and overall satisfaction according to age (Table 3), 
smoking status (Table 4), and duration of COPD (Table 5) 
did not reveal statistically significant differences between 
the Respimat® and Breezhaler® patient groups.
Discussion
This cross-sectional study had three important findings. 
First, it was shown that patient overall satisfaction, includ-
ing with the performance and convenience of the Respimat® 
SMI12 compared with the Breezhaler® DPI,13 was similar in 
patients with stable COPD, as measured by the validated 
PASAPQ. Second, this analysis showed that patient satis-
faction with the handling and performance of Respimat® 
compared with the Breezhaler® inhaler was independent 
of age, smoking history, and duration of COPD. Third, 
patients gave Respimat® and Breezhaler® overall satisfaction 
PASAPQ scores of 6.0 and 5.9, respectively, which shows 
that both sets of patients were satisfied with the inhaler they 
were assigned.
A modified version of the PASAPQ questionnaire was 
used in this trial, excluding the questions on inhaler prefer-
ence and willingness to continue after the end of the assess-
ment period. The trial did not employ a crossover design, 
and patients used only one device during the study. Inhaler 
preference should be assessed using a randomized, crossover 
design, with the same medication in different devices, and 
for a longer assessment period.14
We explored possible sources of bias including site 
recruitment differences, patient recruitment rates, and the 
quality of device training received by patients enrolled in the 
trial. The majority of patients in both groups were instructed 
by the physician, followed by the nurse (62.4% and 34.9% 
of total number of patients receiving training, respectively). 
In addition, no statistical differences in PASAPQ scores 
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Although there were no major differences in demographic 
variables between the Breezhaler® and Respimat® arms, 
such as, for example, age, sex, time since COPD diagnosis, 
and smoking history, a higher proportion of patients in the 
Respimat® group was previously using inhaled cortico-
steroids (ICS) compared with those in the Breezhaler® arm. 
However, to minimize a positive selection bias, the decision 
to treat patients with Respimat® or Breezhaler® was taken 
before patients were recruited into the study, and this had 
to be in compliance with usual clinical practice at the study 
sites, ie, only patients who already used either device for a 
period of 3–6 months were recruited into the study. Although 
patients on higher ICS use prior to the study observation 
period could have presented a more symptomatic disease 
state than those patients with less use of corticosteroids, this 
was not thought to have a major influence on the results of 
the study. Patients in either group showed similar baseline 
lung function obstruction, as shown by forced expiratory 
volume in 1 second (FEV
1
)% predicted. In this trial, no 
additional data on symptoms scoring (COPD Assessment 
Table 1 Baseline characteristics of patients
Respimat® (n=77) Breezhaler® (n=77) Total (N=154) P-value
age – mean (sD) 69.7 (10.0) 67.0 (9.9) 68.4 (10.0) 0.102
Male – n (%) 69 (89.6) 70 (90.9) 139 (90.3) 0.786
BMI – n (%) 0.063
,18 kg/m2 1 (1.3) 1 (1.3) 2 (1.3)
18 to #30 kg/m2 48 (62.3) 51 (66.2) 99 (64.3)
.30 kg/m2 27 (35.1) 25 (32.5) 52 (33.8)
smoking status – n (%) 0.496
Current smoker 18 (23.4) 15 (19.5) 33 (21.4)
ex-smokers 55 (71.4) 60 (77.9) 115 (74.7)
Pack-years of smoking – mean (sD) 57.9 (26.2) 55.7 (24.7) 56.8 (25.4) 0.605
Time since COPD diagnosis, years – (sD) 6.3 (6.0) 5.9 (5.4) 6.1 (5.7) 0.643
Postbronchodilation spirometry – mean (sD)
FeV1 – liters 1.5 (0.6) 1.6 (0.7) 1.6 (0.6) 0.214
FeV1 – % of predicted value 55.1 (16.5) 56.5 (21.5) 55.8 (19.1) 0.652
FVC – liters 2.8 (0.8) 3.1 (0.9) 3.0 (0.9) 0.035
FVC – % of predicted value 76.2 (16.7) 81.7 (23.4) 78.9 (20.4) 0.098
FeV1/FVC 53.9 (12.9) 51.8 (12.2) 52.9 (12.5) 0.304
respiratory medication – n (%)
Inhaled anticholinergics
long-acting
sPIrIVa® respimat® 77 (100) 0 (0.0) 77 (50.0)
short-acting 8 (10.4) 13 (16.9) 21 (13.6) 0.240
Inhaled β-agonists
long-acting
hirobriz® Breezhaler® 0 (0.0) 16 (20.8) 16 (10.4)
Onbrez® Breezhaler® 0 (0.0) 51 (66.2) 51 (33.1)
Oslif® Breezhaler® 0 (0.0) 10 (13.0) 10 (6.5)
short-acting 46 (59.7) 43 (55.8) 89 (57.8) 0.624
Corticosteroids
Inhaled 52 (67.5) 22 (28.6) 74 (48.1) ,0.001
systemic 3 (3.9) 3 (3.9) 6 (3.9) 1.000
Theophylline 0 (0.0) 2 (2.6) 2 (1.3) 0.497
received training on inhalation technique at 
initial prescription – n (%)
73 (94.8) 76 (98.7) 149 (96.8) 0.367
Instructions given by – n (%)
Doctor 51 (69.9) 42 (55.3) 93 (62.4)
nurse 18 (24.7) 34 (44.7) 52 (34.9)
Pharmacist 2 (2.7) 0 (0.0) 2 (1.3)
Other 1 (1.4) 0 (0.0) 1 (0.7)
Missing 1 (1.4) 0 (0.0) 1 (0.7)
Note: P-values are based on chi-square test or Fisher’s exact test for the categorical variables, and on a two-sample t-test for the continuous variables.


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Device handling and patient satisfaction in COPD
Test, St George’s Respiratory Questionnaire) or exacerbation 
data has been collected. Nevertheless, it cannot be completely 
ruled out that for some patients, the efficacy provided by their 
prescribed treatment, either before or concomitant with the 
observation period, may have influenced their perception of 
the inhaler device.
Patient satisfaction with their inhalers is now acknow-
ledged as an important patient-reported outcome in respira-
tory medicine8 owing to its impact on patients’ adherence to 
their prescribed treatments.15 Patient satisfaction is dependent 
on physical attributes of the inhaler device such as ease of 
use, convenience, robustness, portability, and whether the 
instructions were simple and easy to follow.1,10 The ability 
to be used easily and having multiple doses to reduce the 
need for device preparation are also desirable.1 A reason for 
patient dissatisfaction with their inhalation device might be 
drug deposition to the back of the throat. With prolonged use, 
this causes inflammation in the back of the throat. Therefore, 
improved delivery to the lung of the active compound is 
important for improved patient satisfaction and treatment 
adherence. This can be achieved by having the following 
attributes: formulation of aerosol cloud ,5.8 μm in size, low 
cloud velocity, and cloud generation that is independent of 
patient inspiration rate.1
The decision to compare the Respimat® SMI with the 
Breezhaler® DPI in our study was based on their design 
features; more than other competing devices, they closely 
adhere to key features identified as being important in 
the design of an ideal inhaler device. The Respimat® SMI 
was designed to overcome problems such as limited drug 
deposition in the lung and the reliance on adequate patient 
coordination for effective inhalation. It is a multiple-dose 
device that generates a fine aerosol cloud that is emitted more 
slowly and lasts 1.5 seconds compared with ,0.2 to .0.3 
seconds for chlorofluorocarbon MDIs and hydrofluoroalkane 
pressurized MDIs (HFA pMDIs), respectively.1 In vitro data 
showed a reduced throat deposition using Respimat® SMI 
versus Breezhaler® in patients with moderate/very severe 
COPD. In addition, its delivery mechanism has been opti-
mized to maximize the proportion of the inhaled dose that 
Figure 1 Mean PasaPQ scores by treatment.
Abbreviations: PasaPQ, Patient satisfaction and Preference Questionnaire; sD, standard deviation.
Table 2 PasaPQ scores by treatment
PASAPQ scores Respimat® (n=77) Breezhaler® (n=77) Mean difference (95% CI) P-value
Total score 80.7 (10.5) 79.9 (12.7) 0.8 (-2.9 to 4.5) 0.67
Total performance 82.5 (12.6) 78.2 (15.8) 4.3 (-0.3 to 8.9) 0.06
Total convenience 78.6 (11.3) 81.9 (11.7) -3.3 (-7.0 to 0.4) 0.08
Overall satisfaction 6.0 (0.8) 5.9 (1.2) 0.1 (-0.3 to 0.4) 0.70
Note: Data are mean (SD) unless otherwise specified.
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reaches the patient’s lung.16 The consequence of this is that 
drug exposure and clinical efficacy is achieved at a much 
lower tiotropium dose, compared with the HandiHaler® DPI 
(18 μg for SPIRIVA® HandiHaler®). Using the Breezhaler® 
DPI, the dose of indacaterol is either 150 or 300 μg. In the 
current study, these advantages of the Respimat® SMI were 
not assessed directly and therefore not detected by patients 
in the Respimat® SMI group.
The Breezhaler® is a low airflow resistance, single-
dose DPI. It is designed in such a way that the drug/carrier 
mixture is partly dispersed into inhalable drug particles by 
the inspiratory airflow of the patient. The extent of device 
emptying and dispersion, which determines the fine-particle 
dose of drug emitted, depends strongly on the inspiratory 
airflow and absolute lung capacity, both of which differ from 
patient to patient.1
Other studies have previously investigated patient satis-
faction and preference for inhalers, but these have differed 
in their assessment of this outcome measure.14,17 This has 
been due to differences in the instruments that have been 
used to gauge patient satisfaction and preference for a given 
inhaler.1,17 Instruments have included simple preference 
questionnaires and nonvalidated proprietary questionnaires 
with poorly defined response scales, developed without 
psychometric testing. To date, only two instruments, the 
PASAPQ and the Patient Device Experience Assessment, 
Figure 2 Distribution of total PasaPQ scores.
Abbreviation: PasaPQ, Patient satisfaction and Preference Questionnaire.




#70 years .70 years
Total score
respimat® 80.1 (12.4) 81.3 (8.2) 0.62
Breezhaler® 81.8 (11.2) 77.1 (14.4) 0.11
Total performance
respimat® 81.0 (15.4) 84.0 (8.7) 0.30
Breezhaler® 80.7 (13.4) 74.5 (18.5) 0.09
Total convenience
respimat® 79.1 (12.7) 78.1 (9.8) 0.72
Breezhaler® 83.1 (10.8) 80.2 (13.1) 0.29
Overall satisfaction
respimat® 6.0 (1.0) 6.0 (0.6) 0.88
Breezhaler® 6.1 (1.2) 5.6 (1.2) 0.04
Note: Data are mean (SD) unless otherwise specified.
Abbreviations: PasaPQ, Patient satisfaction and Prefer ence Questionnaire; sD, 
standard deviation.






respimat® 82.8 (11.5) 79.8 (10.4) 0.30
Breezhaler® 76.1 (10.7) 80.8 (13.1) 0.20
Total performance
respimat® 82.7 (14.1) 82.2 (12.5) 0.89
Breezhaler® 73.8 (13.7) 79.3 (16.2) 0.23
Total convenience
respimat® 83.0 (10.7) 77.1 (11.5) 0.06
Breezhaler® 78.7 (11.5) 82.5 (11.9) 0.27
Overall satisfaction
respimat® 6.2 (0.9) 5.9 (0.8) 0.19
Breezhaler® 5.3 (1.7) 6.1 (1.0) 0.02
Note: Data are mean (SD) unless otherwise specified.


















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Device handling and patient satisfaction in COPD
have incorporated input from experts in psychometric test-
ing and have been subjected to field testing. Of these two, 
only the PASAPQ has a published validation.11 Based on 
the validation reported by Kozma et al,11 which assessed 
validity, reliability, and responsiveness, and explored 
the between-group difference in PASAPQ scores across 
asthma, COPD, and mixed respiratory diseases, the 
PASAPQ is a practical, reliable, valid, and responsive 
instrument for measuring device satisfaction in respira-
tory diseases.
Our scores for the overall patient satisfaction, perfor-
mance, and convenience domains for the Respimat® SMI are 
consistent with those from previous trials that utilized the 
PASAPQ to assess patient satisfaction.18–21 In these studies, 
which were conducted in patients with asthma, COPD, or 
both, patient satisfaction for the Respimat® SMI was com-
pared with that of the HFA pMDI, and the DPIs Turbuhaler®
 
and Diskus®, using the PASAPQ. The durations of these 
studies ranged from 4 to 48 weeks.18–21 In Schurmann et al’s 
study,18 a crossover study that compared the Respimat® SMI 
to the HFA pMDI, patients were trained in inhaler use at the 
beginning of each treatment period and given #5 attempts 
to demonstrate satisfactory technique; however, use of the 
inhalers prior to randomization was not permitted. Similarly, 
Hodder et al’s study,19 which had a parallel-group, double-
dummy design, did not enroll patients with prior use of the 
inhalers under evaluation. Patient performance and conve-
nience domain scores for the Respimat® SMI ranged from 
81.6 to 88.2 and from 78.6 to 83.6, respectively, compared 
with 82.5 and 78.6 for the performance and convenience 
domains, respectively, in our current study.




Time since COPD diagnosis P-value
#6 years .6 years
Total score
respimat® 79.6 (12.3) 82.3 (6.9) 0.28
Breezhaler® 80.0 (12.8) 79.9 (12.7) 0.98
Total performance
respimat® 80.5 (14.8) 85.5 (7.6) 0.09
Breezhaler® 78.2 (15.4) 78.2 (16.8) 0.99
Total convenience
respimat® 78.7 (13.0) 78.6 (8.4) 0.98
Breezhaler® 82.0 (12.3) 81.9 (11.1) 0.96
Overall satisfaction
respimat® 5.9 (1.0) 6.0 (0.5) 0.73
Breezhaler® 5.8 (1.3) 6.0 (1.0) 0.43
Note: Data are mean (SD) unless otherwise specified.
Abbreviations: COPD, chronic obstructive pulmonary disease; PasaPQ, Patient 
satisfaction and Prefer ence Questionnaire; sD, standard deviation.
When comparing DPIs with the Respimat® SMI, the 
main difference between the current study and other trials 
that used PASAPQ to assess patient satisfaction for a given 
inhaler was the relatively higher scores for the Breezhaler® 
DPI compared with other DPIs. In previous comparator stud-
ies with Respimat® SMI, DPIs (Turbuhaler® and Diskus®) 
received mean total, performance domain, and convenience 
domain PASAPQ scores ranging from 75.5 to 76.9, 72 to 
75.5, and 75.4 to 82.7, respectively.19,20 This compares with 
79.9, 78.2, and 81.9 for mean total, performance domain, 
and convenience domain PASAPQ scores, respectively, for 
Breezhaler®.
In conclusion, patients with COPD in Spain who used 
either the Respimat® SMI or the Breezhaler® DPI reported 
being similarly satisfied with the performance and conve-
nience of each inhaler. Furthermore, these results suggest that 
the use of either of these inhalers would encourage treatment 
adherence in patients with COPD.
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Device handling and patient satisfaction in COPD
Table S1 Validated questions included in the modified PASAPQ
Domain Question Description
Total score
Performance domain Q1 Overall feeling of inhaling
Q2 Inhaled dose goes to lungs
Q3 amount of medication left
Q4 Works reliably
Q5 ease of inhaling a dose
Q10 Using the inhaler
Q11 speed medicine comes out
Convenience domain Q6 Instructions for use
Q7 size of inhaler
Q8 Durability of inhaler
Q9 ease of cleaning inhaler
Q12 ease of holding during use
Q13 Convenience of carrying
Q14 Overall satisfaction
Notes: all items scored on a 7-point likert scale: 1= very dissatisfied, 2= dissatisfied, 
3= somewhat dissatisfied, 4= neither satisfied nor dissatisfied, 5= somewhat satisfied, 
6= satisfied, 7= very satisfied.
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